Metastatic triple-negative breast cancer: A population based study

被引：0
|
作者：
Ess, S. [1 ]
Jochum, W. [2 ]
Oehlschlaegel, C. [2 ]
Thuerlimann, B. [3 ]
机构：
[1] Krebsliga St Gallen Appenzell, Canc Registry, St Gallen, Switzerland
[2] Inst Pathol, St Gallen, Switzerland
[3] Kantonsspital, Breast Ctr, St Gallen, Switzerland
来源：
BREAST | 2011年 / 20卷
关键词：
D O I：
10.1016/S0960-9776(11)70259-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [1] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    [J]. CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [2] Metastatic Triple-Negative Breast Cancer
    Zhang, Xiaojie
    Yeung, Kay T.
    [J]. CURRENT BREAST CANCER REPORTS, 2023, 15 (03) : 288 - 297
  • [3] Metastatic Triple-Negative Breast Cancer
    Xiaojie Zhang
    Kay T. Yeung
    [J]. Current Breast Cancer Reports, 2023, 15 : 288 - 297
  • [4] Atezolizumab for metastatic triple-negative breast cancer
    Stirrups, Robert
    [J]. LANCET ONCOLOGY, 2018, 19 (10): : E519 - E519
  • [5] Iniparib in Metastatic Triple-Negative Breast Cancer
    Domagala, Pawel
    Lubinski, Jan
    Domagala, Wenancjusz
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (18): : 1780 - 1780
  • [6] Treatment of Metastatic Triple-Negative Breast Cancer
    Glendenning, Jennifer
    Irshad, Sheeba
    Tutt, Andrew
    [J]. CURRENT BREAST CANCER REPORTS, 2012, 4 (01) : 10 - 21
  • [7] Treatment of Metastatic Triple-Negative Breast Cancer
    Jennifer Glendenning
    Sheeba Irshad
    Andrew Tutt
    [J]. Current Breast Cancer Reports, 2012, 4 (1) : 10 - 21
  • [8] Race and triple-negative breast cancer survival: A population-based study
    Liu, Ying
    Lian, Min
    Colditz, Graham A.
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [9] Triple-negative breast cancer in the older population
    Boyle, P.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 7 - 12
  • [10] Pembrolizumab monotherapy in metastatic triple-negative breast cancer
    Amir, Eitan
    Cescon, David W.
    [J]. LANCET ONCOLOGY, 2021, 22 (04): : 415 - 417
12345